Navigation Links
Organogenesis Awarded a 5-Year Federal Supply Schedule Agreement with the Department of Veteran Affairs

CANTON, Mass., Aug 4, 2014 /PRNewswire/ -- Organogenesis Inc. announced today that it has been awarded Federal Supply Schedule Contract V797D-30288 with the Department of Veterans Affairs (VA) for Apligraf®, the only product with FDA approval for the treatment of both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).  This five-year contract includes an option to extend its duration for an additional five years, for a total contract duration of up to 10 years.   This award will streamline the purchasing process for Veterans Affairs Medical Centers to gain easier access to Apligraf. 

The VA Federal Supply Schedule program is managed by the VA under delegated authority by the General Services Administration (GSA).  The VA manages Schedule programs for medical equipment, supply, pharmaceutical, and service contracts. 

"This is a positive event for veterans and patients within the VA system who suffer from DFUs and VLUs, as they will have improved access to Apligraf, which is now on contract within the VA Medical Centers and Community-Based Outpatient Clinics," said Geoff MacKay, President and CEO of Organogenesis Inc.  "Apligraf has been proven to close these chronic wounds faster than standard care alone, and lower amputation rates have been observed, which is especially important in the VA system.  Research has shown that closing wounds rapidly is critical in preventing complications such as amputations or osteomyelitis."

Diabetic foot ulcers and venous leg ulcers are among the most frequently occurring chronic wounds, affecting millions of people in the United States every year, including many U.S. veterans. Research has shown that the majority of patients with VLUs or DFUs fail to heal with conventional therapy alone. These low success rates contribute to both the costs and risks associated with chronic wounds.

With Apligraf, clinicians have a bioengineered living cell-based treatment for wounds that fail to adequately respond to conventional therapy.  Recent findings highlighting the significant burden of these debilitating chronic wounds underscore the urgent need for improved identification, prevention and aggressive treatment. [1],[2]

Diabetes affects about 1 million veterans within the VA health care system, which is nearly 20% of the patients the Department sees each year (compared to 8% of the total U.S. population).[3],[4] Diabetes is also the leading cause of blindness, end-stage renal disease, and amputation for VA patients. [5]  A recent retrospective study found that VA patients with a new diagnosis of a diabetic foot ulcer had significantly higher amputation rates compared to patients treated in adjacent private and public hospitals (6.8% private, 12% public and 23.5% VA, p< 0.001). [6]

About Apligraf
Apligraf contains two layers of human living cells: a layer of differentiated keratinocytes and a layer of fibroblasts in a collagen matrix. When placed on a wound previously unresponsive to treatment, Apligraf provides cells, collagen matrix, and other proteins, and has been demonstrated to promote healing. In controlled clinical studies, Apligraf has been shown to be an effective and safe wound care treatment, superior to conventional treatments alone.  Clinical studies of Apligraf application were based on up to 5 treatments, comprising weekly assessments and/or applications, over a 12-week period. Over 650,000 Apligraf units have been shipped for patient application.  The product is covered by Medicare, Medicaid and more than 1,500 private insurers.

About Organogenesis Inc.
Having pioneered the field, Massachusetts-based Organogenesis Inc. is a world leading regenerative medicine company focused in the areas of bio-active wound healing and soft tissue regeneration. The company's mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care. For more information, visit

[1] Rice JB, U Desai, AK Cummings, HG Birnbaum, M Skornicki, N Parsons. Medical, drug, and work-loss costs of diabetic foot ulcers [ISPOR abstract A12]. Value in Health. 2013; 16(3): A12.
[2] Rice JB, U Desai, AK Cummings, HG Birnbaum, M Skornicki, N Parsons. Medical, drug, and work-loss costs of venous leg ulcers [ISPOR abstract A73].  Value in Health. 2013; 16(3): A73.
[3] American Diabetes Association. Accessed April 5, 2013.
[4] Understanding the complex link between diabetes and cognitive health. July 11, 2012. Accessed April 5, 2013. 
[5] Ibid.
[6] Blumberg SN, Warren SM. Disparities in initial presentation and treatment outcomes of diabetic foot ulcers in a public, private and VA hospital. J Diabetes. 2013. doi:10.1111/1753-0407.12050.

Angelyn Lowe
(858) 754-5421

Photo -

SOURCE Organogenesis Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers
2. Organogenesis Announces Annual College Scholarship Award Winner
3. NeuroPhage Awarded Second Grant from Michael J. Fox Foundation for Parkinsons Disease Research
4. Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine
5. CNTS Awarded $40 Million Contract Supporting U.S. Military Through Global Public Health
6. ITRA Global’s Detroit Affiliate Awarded Contract to Manage Real Estate for Michigan’s Western and Southeastern Regions
7. Great Lakes NeuroTechnologies Awarded Patent For Sensor Based Continuous Parkinsons Assessment During Daily Activities
8. Cedar Crest College Awarded Significant Grant from the National Science Foundation
9. Faithful+Gould Joint Venture Awarded IO&T Project At Fort Detrick, MD
10. Harrisvaccines Awarded National Institute of Food and Agriculture Grant for Swine Disease Research
11. Lpath Awarded NIH SBIR Grant for Lpathomab
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today ... Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an ... turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of turfgrass ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
Breaking Biology News(10 mins):